TY - JOUR
T1 - Granulocyte colony-stimulating factor for the treatment of cardiovascular diseases: An update with a critical appraisal
AU - D'Amario, Domenico
AU - Leone, Antonio Maria
AU - Borovac, Josip Anđelo
AU - Cannata, Francesco
AU - Siracusano, Andrea
AU - Niccoli, Giampaolo
AU - Crea, Filippo
PY - 2018
Y1 - 2018
N2 - Heart failure and acute myocardial infarction are conditions that are associated with high morbidity and mortality. Significant dysfunction of the heart muscle can occur as the consequence of end-stage chronic cardiovascular diseases or acute ischemic events that are marked by large infarction area and significant tissue necrosis. Despite the remarkable improvement of conventional treatments, a substantial proportion of patients still develops severe heart failure that can only be resolved by heart transplantation or mechanical device implantation. Therefore, novel approaches based on stem-cell therapy can directly modify the disease process and alter its prognosis. The ability of the stem-cells to modify and repair the injured myocardium is a challenging but intriguing concept that can potentially replace expensive and invasive methods of treatment that are associated with increased risks and significant financial costs. In that sense, granulocyte colony-stimulating factor (G-CSF) seems as an attractive treatment approach. Based on the series of pre-clinical experiments and a limited amount of clinical data, it was demonstrated that G-CSF agents possess the ability to mobilize stem-cells from bone marrow and induce their differentiation into cardiomyocytes or endothelial cells when brought into contact with injured regions of the myocardium. However, clinical benefits of G-CSF use in damaged myocardium remain unclear and are the topic of expert discussion. The main goal of this review is to present relevant and up-to-date evidence on G-CSF therapy use in pre-clinical models and in humans and to provide a rationale for its potential clinical applications in the future.
AB - Heart failure and acute myocardial infarction are conditions that are associated with high morbidity and mortality. Significant dysfunction of the heart muscle can occur as the consequence of end-stage chronic cardiovascular diseases or acute ischemic events that are marked by large infarction area and significant tissue necrosis. Despite the remarkable improvement of conventional treatments, a substantial proportion of patients still develops severe heart failure that can only be resolved by heart transplantation or mechanical device implantation. Therefore, novel approaches based on stem-cell therapy can directly modify the disease process and alter its prognosis. The ability of the stem-cells to modify and repair the injured myocardium is a challenging but intriguing concept that can potentially replace expensive and invasive methods of treatment that are associated with increased risks and significant financial costs. In that sense, granulocyte colony-stimulating factor (G-CSF) seems as an attractive treatment approach. Based on the series of pre-clinical experiments and a limited amount of clinical data, it was demonstrated that G-CSF agents possess the ability to mobilize stem-cells from bone marrow and induce their differentiation into cardiomyocytes or endothelial cells when brought into contact with injured regions of the myocardium. However, clinical benefits of G-CSF use in damaged myocardium remain unclear and are the topic of expert discussion. The main goal of this review is to present relevant and up-to-date evidence on G-CSF therapy use in pre-clinical models and in humans and to provide a rationale for its potential clinical applications in the future.
KW - Granulocyte colony-stimulating factor
KW - Heart failure
KW - Myocardial infarction
KW - Pharmacology
KW - Stem cells
KW - Granulocyte colony-stimulating factor
KW - Heart failure
KW - Myocardial infarction
KW - Pharmacology
KW - Stem cells
UR - http://hdl.handle.net/10807/117004
UR - http://www.elsevier.com/inca/publications/store/6/2/2/9/3/1/index.htt
U2 - 10.1016/j.phrs.2017.06.001
DO - 10.1016/j.phrs.2017.06.001
M3 - Article
SN - 1043-6618
VL - 127
SP - 67
EP - 76
JO - Pharmacological Research
JF - Pharmacological Research
ER -